For every 500 people reading this, one likely has a disease called hypertrophic cardiomyopathy (HCM). It is the most common genetic heart condition in the world, primarily caused by mutations that thicken heart muscle and, in rare cases, lead to heart failure and cardiac arrest.

Today, the Allen Institute for Cell Science launched a set of tools to accelerate research into this global health issue: six new cell line collections, each carrying a different mutation associated with HCM. These cells will help scientists worldwide investigate the impact of specific mutations in myosin, a protein that powers heart contractions, on heart function.

The Institute also released cell line collections targeting skeletal muscle disorders, specifically those related to a myosin mutation, and laminopathies, rare diseases caused by mutations in proteins that maintain a cell’s nucleus.

“Providing researchers with these robust tools paves the way for the discovery of new treatments and insights into disease progression,” said Ru Gunawardane, Ph.D., Executive Director of the Allen Institute for Cell Science. “These cell lines are a perfect bridge between our expertise and the efforts of leading scientists to tackle disease.”

Gene-edited tools

The Allen Cell Catalog’s latest offerings are known as human induced pluripotent stem cells (hiPSCs). These are adult skin cells that have been reprogrammed back into their stem cell form. Using CRISPR/Cas9 technology, Allen Institute scientists introduced disease-associated mutations into these cells along with fluorescent tags that illuminate the structures that drive heart contractions.

Researchers can use these cells to generate cardiac muscle cells, providing a dynamic model to investigate the intricate biomechanics of heart disease.

The Allen Institute has long used CRISPR to insert fluorescent molecules into a cell’s genome. These fluorescent tags allow scientists to visualize and track proteins within cells. Developing the HCM tools offered an opportunity to try a new technique: altering single base pairs of DNA.

The combination of these gene editing methods enabled Allen Institute scientists to rapidly create a series of disease-specific cell lines, said Brock Roberts, Ph.D., a Scientist at the Allen Institute.

“This is the beginning of a different era in human health, where the scalpels and implements of surgery have become molecular,” he said. “We’re still quite a ways from regularly doing that in patients, but this was an exciting opportunity to get into the early stages of research in a human cell.”

Partnering in the lab to make progress in the clinic

Today’s release of the HCM cell lines stems from a collaboration among scientists at the University of Washington, Stanford, and the University of California, Santa Barbara. Their goal was to explore why the mutations linked to HCM cause varying symptoms in patients: some display few or no symptoms, while others, even within the same family, suffer from severe illness.

The team turned to the Allen Institute for Cell Science, which leveraged their decade of experience making gene-edited stem cell lines to generate a robust suite of cells that could be used for this sensitive research.

“Working with the Allen Institute for Cell Science, we knew we were getting high-quality stem cells,” said Stanford University’s Daniel Bernstein, M.D. “If we did this on our own, it would have taken us several years and would have been extraordinarily expensive, and it would have eaten up a large part of the budget of the grant we had gotten from the NIH.”

The cell lines serve as a platform to study myosin mutations across molecular, cellular, and tissue levels, offering a comprehensive understanding of their impact on heart function.

The approach has already proven effective. The researchers’ first study confirmed that a specific rare mutation causes abnormal heart function at all biological levels, countering prior skepticism about its clinical significance.

“Being able to study this in the dish was really important because some cardiologists were beginning to doubt whether this mutation really caused the disease,” said Bernstein, the senior author on the study.

The cells lines also provide opportunities to observe how the disease develops over time, potentially revealing critical phases where targeted interventions might alter or halt its progression.

“Most of the studies we do in human tissue are at the end stage of disease,” said Michael Regnier, Ph.D., a professor of bioengineering at the University of Washington involved with the study. “But what we really want to know is: how is the disease initiated, and how does it progress over time? These cell lines let us do that.”

‘An invaluable resource’

Today’s releases introduce the first disease-specific cell line collections in the Allen Cell Catalog, with hopefully more to come, said Jacqueline Smith, M.S., a senior research associate.

“As an institute, we’ve been really focused on how normal cells function,” Smith said. “Now we’re exploring them in a diseased state to deepen our understanding of these genetic conditions and hopefully lead to new treatments.”

For now, Allen Institute researchers hope these cell lines will illuminate how subtle changes in myosin lead to disfunction at the cellular and tissue levels.

At least one collaborator confirms they already are.

“Studies of cardiomyocytes derived from the Allen Institute for Cell Science’s cell lines enable us to understand how those molecular changes manifest at the sarcomeric and cellular levels,” said Kathleen Ruppel, M.D., Ph.D., a pediatric cardiologist and investigator at Stanford University. “These lines are an invaluable resource to the cardiac muscle community and will lead to important insights into hypertrophic cardiomyopathy.”